Page last updated: 2024-12-08

sc 52151

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SC 52151: HIV protease inhibitor containing the (hydroxylethyl)urea isostere; R-isomer is 1700 times more active than S-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID382974
CHEMBL ID322241
CHEBI ID177730
SCHEMBL ID623164
MeSH IDM0212281

Synonyms (35)

Synonym
CHEMBL322241
(hydroxyethyl)urea isostere deriv. 11
(2s)-n-[(2s,3r)-4-[tert-butylcarbamoyl(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
CHEBI:177730
n-[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)am ino]-2r-hydroxy-1s-(phenylmethyl)propyl]-2s-((2-quinolinylcarbonyl)amino)butanediamide
nsc-670881
telinavir (usan/inn)
D03842
(2s)-n-[(1s,2r)-1-benzyl-3-[tert-butylcarbamoyl(isobutyl)amino]-2-hydroxy-propyl]-2-(quinoline-2-carbonylamino)butanediamide
sc 52151
n-tert-butyl-n'-isobutyl-n'-[2(r)-hydroxy-4-phenyl-3(s)-[4-amino-1,4-dioxo-2(s)-(2-quinolinylcarboxamido)butylamino]butyl]urea
telinavir
143224-34-4
sc-52151 ,
sc52151
nsc670881
(2r)-n-[(2s)-4-[tert-butylcarbamoyl(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
telinavir [usan:inn]
butanediamide, n1-(3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (1s-(1r*,(r*),2s*))-
unii-izf55eh3cg
butanediamide, n1-((1s,2r)-3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2s)-
butanediamide, n(sup 1)-(3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (1s-(1r*(r*),2s*))-
nsc 670881
(1s-(1r*,(r*),2s*))-n1-(3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)butanediamide
(2s)-n-((1s,2r)-1-benzyl-3-(3-tert-butyl-1-isobutylureido)-2-hydroxypropyl)-2-quinaldamidosuccinamide
izf55eh3cg ,
(2s)-n-[(1s,2r)-1-benzyl-3-(3-tert-butyl-1-isobutylureido)-2-hydroxypropyl]-2-quinaldamidosuccinamide
telinavir [inn]
n-(3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)-amino)-2r-hydroxy-1s-(phenylmethyl)propyl)-2s-((2-quinolinylcarbonyl)amino)butanediamide
telinavir [usan]
SCHEMBL623164
DB12178
Q27280973
2,5,7-triazaspiro[3.4]octan-8-one, hydrochloride (1:1)
bdbm50526874

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of [14C]SC-52151 is 17% when it is administered as an elixir to the rat, dog, or monkey."( SC-52151, a novel inhibitor of the human immunodeficiency virus protease.
Bryant, M; Clare, M; DeCrescenzo, G; Dillard, R; Getman, D; Heintz, R; Houseman, K; Lansky, D; Marr, J; Smidt, M, 1995
)
0.29
" SC-52151, an HIV protease inhibitor, is mainly metabolized by CYP3A4 and is poorly bioavailable after oral administration."( Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole.
Salamon, CM; Schoenhard, GL; Snook, SS; Stolzenbach, JC; Yuan, JH, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Dogs were dosed daily with ketoconazole at dose of 100 mg ketoconazole per dog (approximately 10 mg/kg) for 5 days prior to the initiation of coadministration of SC-52151 for 15 days."( Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole.
Salamon, CM; Schoenhard, GL; Snook, SS; Stolzenbach, JC; Yuan, JH, 1997
)
0.3
" Forty-nine patients received the elixir or SEDDS at a dosage of 750 mg three times daily or 1125 mg twice daily for 14 days."( Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.
Fischl, MA; Flexner, C; Haubrich, R; Holden-Wiltse, J; Karim, A; Meehan, PM; Para, MF; Richman, DD; Yeramian, P, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
asparagine derivativeAn amino acid derivative resulting from reaction of asparagine at the amino group, the carboxy group, or the carboxamide, or from the replacement of any hydrogen of asparagine by a heteroatom. The definition normally excludes peptides containing asparagine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)IC50 (µMol)0.00600.00020.10421.7000AID1795254
Protease Human immunodeficiency virus 1IC50 (µMol)0.00600.00010.22487.3200AID162056
Protease Human immunodeficiency virus 1IC50 (µMol)0.00630.00000.81769.8500AID1604602
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Human rhinovirus sp.EC50 (µMol)0.02100.00500.09320.4400AID160779
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1795254Protease Inhibition Assay from Article 10.1021/jm00054a014: \\Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.\\1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.
AID160780Toxic dose required for 50% in uninfected cells1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.
AID160779Effective concentration necessary to inhibit 50% HIV-induced cell death.1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.
AID1604602Inhibition of HIV-1 protease by spectrofluorometric assay2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.
AID162056Inhibition of HIV-1 Protease.1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (90.91)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.76 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]